Hikma will pay approximately US$2.65 billion for the generics business (US$1.18 billion in cash and 40 million new Hikma shares) and believes the deal will make it the sixth largest US generics provider. The company has also agreed to make milestone payments of up to US$125 million.

Hikma will gain 88 generics in specialized and niche segments of the market, including oncology, respiratory, extended release and controlled substances. Hikma’s pipeline will also be enhanced by adding 89 R & D projects, including 57 Paragraph IV products, 13 of which are first-to-file opportunities.

This is not the first time Hikma has looked to expand its presence in the US. The company also acquired some of Baxter’s injectable products sold primarily in the US back in 2011 [1].

Related article
Hikma makes deal to enhance delivery of generic injectables

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Hikma buying into the US market [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 21]. Available from: www.gabionline.net/Pharma-News/Hikma-buying-into-the-US-market

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.